About mink therapeutics inc - INKT
MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company was founded by Garo H. Armen in 2017 and is headquartered in New York, NY.
INKT At a Glance
MiNK Therapeutics, Inc.
149 Fifth Avenue
New York, New York 10010
| Phone | 1-212-994-8250 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -12,494,260.00 | |
| Sector | Health Technology | Employees | 15 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
INKT Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -3.205 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.131 |
INKT Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -832,950.667 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
INKT Liquidity
| Current Ratio | 1.063 |
| Quick Ratio | 1.063 |
| Cash Ratio | 1.025 |
INKT Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -125.195 |
| Return on Equity | N/A |
| Return on Total Capital | 138.085 |
| Return on Invested Capital | N/A |
INKT Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | -57.243 |
| Total Debt to Total Assets | 36.375 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |